Damora Therapeutics, Inc. current report, 16 September 2024

SEC Filing Summary: Galecto, Inc. (GLTO)

Business Context and Reporting Period

This Form 8-K was filed by Galecto, Inc. on September 16, 2024. The company is a biopharmaceutical entity incorporated in Delaware and listed on The Nasdaq Capital Market under the symbol GLTO. The report addresses a specific regulatory event regarding the company's listing status.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance event and does not contain financial statements or performance data.

Material Changes

The primary material change reported is the resolution of a prior listing deficiency. The Nasdaq Listing Qualifications Department determined that the company regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). Specifically, the closing bid price of the common stock was at $1.00 per share or greater for the period from August 30 to September 13, 2024. Consequently, the matter regarding the minimum bid price deficiency is now closed.

Guidance, Outlook, and Risks

The filing contains no management commentary, financial guidance, or outlook. No new risks, contingencies, or unusual items were disclosed in this specific report beyond the resolution of the listing compliance issue.

Key Facts for Investor Verification

  • Confirm that the Nasdaq listing deficiency regarding minimum bid price is officially closed as of September 16, 2024.
  • Verify the current trading price of GLTO to ensure continued compliance with the $1.00 minimum bid price requirement.
  • Note that this filing does not contain updated financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.